Last reviewed · How we verify
NCT06604715
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 trial testing JNJ-87562761 in Relapsed or Refractory Multiple Myeloma in 80 participants. Currently enrolling.
3 November 2027
Quick facts
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 19 December 2024 |
| Primary completion | 3 November 2027 |
| Estimated completion | 15 November 2027 |
| Sites | 15 locations across Taiwan, Canada, Spain, South Korea |
Drugs / interventions tested
- JNJ-87562761 — full drug profile →
Conditions studied
- Relapsed or Refractory Multiple Myeloma — all drugs for Relapsed or Refractory Multiple Myeloma →
Sponsor
Janssen Research & Development, LLC — full company profile →
Who can join
18 and older, any sex, with Relapsed or Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D\[s\]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with multiple myeloma (MM) whose disease has come back after treatment (relapsed) or hasn't responded to treatment (refractory).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06604715
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed or Refractory Multiple Myeloma
Currently open trials in the same condition.
- NCT07369895 — Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07116616 — A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT07312188 — A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT06574568 — A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT06425991 — A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · active not recruiting
Other Janssen Research & Development, LLC trials
Trials by the same sponsor.
- NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
- NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
- NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
- NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
- NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06604715 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06604715.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing